Abstract
Introduction
This retrospective study aimed to investigate that if switch of combination antiretroviral therapy (cART) would result in viral suppression (<40 copies/mL) at 48 weeks for patients with persistent low-level viremia after having received cART for six months or more at two hospitals designated for HIV care in Taiwan.
Materials and Methods
Between January 2001 and January 2013, patients were enrolled if plasma HIV RNA load (PVL) were >20 to <1000 copies/mL detected for six months or more [1, 2]. Using a standardized data collection form, we recorded data of PVL and CD4 count before cART and at the detection of low-level viremia, serologies for hepatitis B and C virus, risk factors, duration of cART exposure, years of HIV diagnosed and ever experiencing treatment failure. The strategy of switch is based on the clinical guidelines of BHIVA, which suggest change of cART from non-nucleoside reverse-transcriptase inhibitors (nNRTIs) or unboosted protease inhibitor (PI) to boosted PI, newer boosted PI or ARV of different mechanism [3].
Results
In this study, 165 patients were enrolled, 119 patients (72.1%) did not switch (Group 1), and 46 patients (27.9%) switched previous regimens to ARV of different mechanism (Group 2). The two groups differed significantly in the proportion of injecting drug users (IDU) (Group 1 vs Group 2, 10.9 vs 26.1%) and median PVL (67 vs 159 copies/mL), and the proportion of PVL<200 copies/mL (84.0% vs 58.7%) when low-level viremia was first detected. In Group 1, 39 (32.8%) continued two nucleoside reverse-transcriptase inhibitors (NRTIs) plus nNRTI; 29 (24.4%) 2 NRTIs plus PI, 47 (39.5%) 2 NRTIs plus boosted PI, and 4 (3.3%) 2 NRTIs plus integrase inhibitor (II). In Group 2, two (4.3%) switched to 2 NRTIs plus PI, 38 (82.6%) 2 NRTIs plus boosted PI, three (6.5%) 2 NRTIs plus II and three (6.5%) boosted PI plus II. In multivariate analysis, IDUs (adjusted odds ratio [AOR], 6.757; 95% CI 2.427–18.868) and PVL of 200–999 copies/mL at enrollment (AOR, 4.902; 95% CI 1.992–12.048) were more likely to be switched. At 48 weeks, patients in Group 2 were more likely to achieve PVL<40 copies/mL than Group 1 (82.6% vs 63.0%, p=0.016), while no difference was observed in achieving PVL <200 copies/mL between the two groups (95.7% vs 92.4%, p=0.729).
Conclusions
According to the clinical guidelines of BHIVA, patients with low-level viremia who switched to cART consisting of 2 NRTIs plus boosted PI or newer mechanisms were more likely to re-establish viral suppression to <40 copies/mL at week 48.
Table 1.
Characteristics of patients with persistent low level viremia
| Total (n=165) | No switch of cART (n=119) | Switch of cART (n=46) | p | |
|---|---|---|---|---|
| Age±SD (y/o) | 39±11 | 38±11 | 41±10 | 0.096 |
| Male (%) | 158 (95.8%) | 114 (95.8%) | 44 (95.7%) | 0.967 |
| MSM (%) | 122 (73.9%) | 91 (76.5%) | 31 (67.4%) | 0.242 |
| IDU (%) | 25 (15.2%) | 13 (10.9%) | 12 (26.1%) | 0.027 |
| HBV (%) | 19 (11.5%) | 14 (11.8%) | 3 (6.5%) | 0.810 |
| HCV (%) | 28 (17.0%) | 17 (14.3%) | 9 (19.6%) | 0.330 |
| Before cART CD4, median (range), cells/uL | 184 (1–928) | 187 (1–707) | 171 (10–928) | 0.937 |
| Before cART PVL, median, copies/mL, log10 | 5.29 | 5.29 | 5.29 | 0.312 |
| PVL>5 log10 (%) | 98 (59.4%) | 73 (61.3%) | 25 (54.3%) | 0.480 |
| CD4 at LLV, median (range), cells/uL | 422 (63–1092) | 419 (63–1092) | 431 (134–1010) | 0.156 |
| PVL at enrollment, copies/mL | 83 (21–999) | 67 (21–939) | 159 (21–999) | 0.002 |
| PVL of 20–199 (%) | 127 (77.0%) | 100 (84.0%) | 27 (58.7%) | 0.001 |
| PVL of 200–999 (%) | 38 (23.0%) | 19 (16.0%) | 19 (41.3%) | 0.001 |
| Duration of cART exposure, median (range), weeks | 47 (12–391) | 44 (15–321) | 58 (12–391) | 0.062 |
| Years of HIV diagnosed, median, (range), years | 4 (1–14) | 4 (1–14) | 4 (2–13) | 0.356 |
| Ever treatment failure (%) | 42/165 | 26/119 | 16/46 | 0.111 |
| Current cART | ||||
| 2NRTIs+nNRTI | 39 (23.6%) | 39 (32.8%) | 0 (0%) | <0.001 |
| 2NRTIs+PI | 31 (18.8%) | 29 (24.4%) | 2 (4.3%) | 0.003 |
| 2NRTIs+PI/r | 85 (51.5%) | 47 (39.5%) | 38 (82.6%) | <0.001 |
| 2NRTIs+II | 7 (4.2%) | 4 (3.3%) | 3 (6.5%) | 0.967 |
| II+PI/r | 3 (1.8%) | 0 (0%) | 3 (6.5%) | 0.021 |
References
- 1.Laprise C, de Pokomandy A, Baril JG, Dufresne S, Trottier H. Virologic failure following persistent low-level viremia in a cohort of HIV-positive patients: results from 12 years of observation. Clin Infect Dis. 2013;57(10):1489–96. doi: 10.1093/cid/cit529. [DOI] [PubMed] [Google Scholar]
- 2.Easterbrook PJ, Ives N, Waters A, Mullen J, O'Shea S, Peters B, et al. The natural history and clinical significance of intermittent viraemia in patients with initial viral suppression to <400 copies/ml. AIDS. 2002;16:1521–7. doi: 10.1097/00002030-200207260-00009. [DOI] [PubMed] [Google Scholar]
- 3.Lohse N, Kronborg G, Gerstoft J, Larsen CS, Pedersen G, Pedersen C, et al. Virological control during the first 6–18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV-infected patients: a Danish, population-based, 6-year follow-up study. Clin Infect Dis. 2006;42:136–44. doi: 10.1086/498515. [DOI] [PubMed] [Google Scholar]